Emergent Biosolutions EBS Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities
Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's payments for (proceeds from) contingent consideration liability (asset), investing activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's payments for (proceeds from) contingent consideration liability (asset), investing activities?
- Emergent Biosolutions (EBS) reported payments for (proceeds from) contingent consideration liability (asset), investing activities of $0 in Q1 2026.
- How has Emergent Biosolutions's payments for (proceeds from) contingent consideration liability (asset), investing activities changed year-over-year?
- Emergent Biosolutions's payments for (proceeds from) contingent consideration liability (asset), investing activities increased by 100.0% year-over-year, from -$30M to $0.
- What does payments for (proceeds from) contingent consideration liability (asset), investing activities mean?
- Tracks the actual cash outflows or inflows related to the settlement of contingent consideration liabilities arising from past acquisitions. Unlike fair value adjustments, this represents the realized cash impact of meeting or missing performance milestones. It provides transparency into the ultimate cash cost of inorganic growth strategies.